URL-101

URL-101 is a small molecule therapeutic candidate being developed by United Research Laboratories (URL). According to company pipeline documentation, the asset is currently in Phase 2 clinical development for the treatment of active ulcerative colitis and has also been evaluated in Phase 1 trials for COVID-19. United Research Laboratories focuses on the development of treatments for inflammatory and infectious diseases, often through the repurposing or reformulation of established compounds. While the specific molecular target and active ingredient for URL-101 have not been explicitly disclosed in public pipeline summaries, the drug is a key component of the company's clinical-stage portfolio addressing systemic and localized inflammation.